Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

copper Cu 64 FAP-2286

A radioconjugate composed of FAP-2286, a fibroblast activation protein (FAP)-targeted peptide, labeled with the radioisotope copper Cu 64, with potential use as a tracer for FAP-expressing cells during positron emission tomography (PET). Upon administration of copper Cu 64 FAP-2286, the FAP-2286 moiety targets and binds to FAP-expressing cancer-associated fibroblasts (CAFs) and FAP-expressing tumor cells. Upon binding, FAP-expressing cells can be detected during PET imaging. FAP, a cell surface protein, is overexpressed on CAFs in the tumor microenvironment (TME) and certain tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	64Cu-FAP-2286 copper-64 labeled FAP-2286

copper Cu 64 FAP-2286

Search NCI's Drug Dictionary